Timber Pharmaceuticals, Inc.
TMBR · AMEX
12/31/2022 | 12/31/2021 | 12/31/2020 | 1/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.01 |
| FCF Yield | -5,159.58% | -730.25% | -929.05% | -43.52% |
| EV / EBITDA | 0.44 | 1.43 | 0.48 | -60.66 |
| Quality | ||||
| ROIC | -345.75% | -75.63% | -193.64% | 264.81% |
| Gross Margin | -15,892.35% | -1,979.40% | -230.78% | -941.95% |
| Cash Conversion Ratio | 0.82 | 0.88 | 0.55 | 0.34 |
| Growth | ||||
| Revenue 3-Year CAGR | -43.20% | -3.06% | 99.68% | 64.45% |
| Free Cash Flow Growth | -69.97% | -3.19% | -636.72% | 91.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 1.55 | 0.54 | 1.25 |
| Interest Coverage | -84.20 | -684.86 | -4.58 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -37.07 | -56.58 | -96.06 | -54.11 |